News
ALPN
64.46
-0.06%
-0.04
Alpine Immune Sciences (ALPN) Price Target Increased by 36.91% to 63.24
NASDAQ · 1d ago
Alpine Immune Sciences Cut to Hold From Buy by TD Cowen
Dow Jones · 1d ago
TD Cowen Downgrades Alpine Immune Sciences to Hold
Benzinga · 1d ago
U.S. RESEARCH ROUNDUP-Advanced Micro Devices, Kroger, Tyson Foods
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Advanced Micro Devices, Kroger and Tyson Foods among companies with new targets. Analysts raise ratings and target prices on several companies. Boeing, Caterpillar and AIG among those with targets raised.
Reuters · 1d ago
ALPINE IMMUNE SCIENCES INC <ALPN.O>: TD COWEN CUTS TO HOLD FROM BUY
Reuters · 2d ago
Weekly Report: what happened at ALPN last week (0408-0412)?
Weekly Report · 2d ago
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
NASDAQ · 5d ago
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed sale of Alpine Immune Sciences, Inc. To Vertex Pharmaceuticals. Under the terms of the proposed transaction, shareholders of Alpine will receive $65.00 in cash for each share of Alpine. KSF is seeking to determine whether the consideration undervalues Alpine.
Barchart · 5d ago
Alpine Immune Sciences Cut to Market Perform From Outperform by Leerink Partners
Dow Jones · 5d ago
Alpine Immune Sciences Price Target Raised to $65.00/Share From $42.00 by Leerink Partners
Dow Jones · 5d ago
Leerink Partners Downgrades Alpine Immune Sciences to Market Perform, Raises Price Target to $65
Benzinga · 5d ago
Vertex Pharmaceuticals: Alpine Accelerates Aspiration To Become Biotech Powerhouse
Vertex Pharmaceuticals is the world's only provider of a gene-based therapy for cystic fibrosis. The acquisition of Alpine Immune Sciences adds another therapy to Vertex's pipeline. Vertex has a $10 billion revenue business and has a pipeline of new therapies.
Seeking Alpha · 5d ago
U.S. RESEARCH ROUNDUP-Cheesecake Factory, Netflix, Texas Roadhouse
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Cheesecake Factory, Netflix, Texas Roadhouse among those with revised targets. Analysts also raise their ratings on Amgen, Boeing and others. The companies are listed on the Nasdaq and NYSE.
Reuters · 5d ago
ALPINE IMMUNE SCIENCES INC <ALPN.O>: LEERINK PARTNERS CUTS TO MARKET PERFORM FROM OUTPERFORM; RAISES TARGET PRICE TO $65 FROM $42
Reuters · 6d ago
Maintaining Hold Rating Amid Vertex Pharmaceuticals’ Acquisition of Alpine Immune Sciences
TipRanks · 6d ago
Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement
Seeking Alpha · 6d ago
US STOCKS-S&P 500, Nasdaq end sharply higher on soft inflation data, eyes on earnings
S&P 500, Nasdaq end sharply higher on soft inflation data. Producer prices index comes in softer than expected. Data rekindles hopes that inflation remains in a cooling trend. Investors focus on first-quarter earnings season. Dow ends essentially unchanged; S&P and Nasdaq close in positive territory.
Reuters · 6d ago
What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences
Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion. Vertex is gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven additional indications. The acquisition also includes Alpine's protein engineering and autoimmune expertise. The deal brings no revenues until at least 2027 and will produce modest upside for Vertex.
Seeking Alpha · 6d ago
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Vertex Pharmaceuticals Incorporated agreed to acquire Alpine Immune Sciences Inc for $65 per share or approximately $4.9 billion in cash. Evercore notes the deal as a surprise move for Vertex. The company has been criticized for its capital allocation in the past.
Benzinga · 6d ago
US STOCKS-Wall Street rebounds on softer inflation data, eyes on earnings
U.S. Stocks rebound from steep sell-off after softer-than-expected inflation data. Producer prices index came in cooler than expected, supporting cooling trend of inflation. The tech-heavy Nasdaq rises sharply, while the S&P 500 and Dow were modestly lower. CarMax drops after Q4 results miss; Rent the Runway surges on artificial intelligence. Investors focus on first-quarter earnings from major banks.
Reuters · 6d ago
More
Webull provides a variety of real-time ALPN stock news. You can receive the latest news about Alpine Immune Sc through multiple platforms. This information may help you make smarter investment decisions.
About ALPN
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.